Overview

  • Product nameAnti-CLN8 antibodySee all CLN8 primary antibodies ...
  • Description
    Rabbit polyclonal to CLN8
  • Tested applicationsWB, ELISAmore details
  • Species reactivity
    Reacts with: Human
    Predicted to work with: Mouse, Horse, Guinea pig, Cat, Dog
  • Immunogen

    Synthetic peptide corresponding to N terminal amino acids 1-49 (MNPASDGGTS ESIFDLDYAS WGIRSTLMVA GFVFYLGVFV VCHQLSSSLN) , of Human CLN8 (NP_061764)

  • Positive control
    • HeLa cell lysate

Properties

Applications

Our Abpromise guarantee covers the use of ab82759 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB Use a concentration of 1 µg/ml. Predicted molecular weight: 33 kDa. Good results were obtained when blocked with 5% non-fat dry milk in 0.05% PBS-T.
ELISA Use at an assay dependent concentration.

ELISA titre using peptide based assay: 1/12500.

Target

  • FunctionCould play a role in cell proliferation during neuronal differentiation and in protection against cell death.
  • Involvement in diseaseDefects in CLN8 are the cause of neuronal ceroid lipofuscinosis type 8 (CLN8) [MIM:600143]. A form of neuronal ceroid lipofuscinosis with onset in childhood. Neuronal ceroid lipofuscinoses are progressive neurodegenerative, lysosomal storage diseases characterized by intracellular accumulation of autofluorescent liposomal material, and clinically by seizures, dementia, visual loss, and/or cerebral atrophy. The lipopigment patterns observed most often in neuronal ceroid lipofuscinosis type 8 comprise mixed combinations of granular, curvilinear, and fingerprint profiles.
    Defects in CLN8 are the cause of neuronal ceroid lipofuscinosis type 8 Northern epilepsy variant (CLN8NE) [MIM:610003]. A form of neuronal ceroid lipofuscinosis clinically characterized by epilepsy that presents between 5 and 10 years of age with frequent tonic-clonic seizures followed by progressive mental retardation. Visual loss is not a prominent feature. Intracellular accumulation of autofluorescent material results in curvilinear and granular profiles on ultrastructural analysis.
  • Sequence similaritiesContains 1 TLC (TRAM/LAG1/CLN8) domain.
  • Post-translational
    modifications
    Does not seem to be N-glycosylated.
  • Cellular localizationEndoplasmic reticulum membrane. Endoplasmic reticulum-Golgi intermediate compartment membrane.
  • Information by UniProt
  • Database links
  • Alternative names
    • C8orf61 antibody
    • Ceroid-lipofuscinosis, neuronal 8 (epilepsy, progressive with mental retardation) antibody
    • Cln8 antibody
    • CLN8 gene antibody
    • CLN8_HUMAN antibody
    • EPMR antibody
    • Protein CLN8 antibody
    see all

Anti-CLN8 antibody images

  • Anti-CLN8 antibody (ab82759) at 1 µg/ml + HeLa cell lysate at 10 µg with skim milk/ PBS at 5 %

    Secondary
    HRP conjugated anti-Rabbit IgG at 1/50000 dilution

    Predicted band size : 33 kDa
    Observed band size : 43 kDa (why is the actual band size different from the predicted?)

References for Anti-CLN8 antibody (ab82759)

ab82759 has not yet been referenced specifically in any publications.

Product Wall

There are currently no Abreviews or Questions for ab82759.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"